Recently, a study about andexanet for reversal of bleeding associated with factor Xa inhibitors has been published . In this multicenter, prospective, open-label, single-group study, 67 patients who had acute major bleeding within 18 h after the administration of a factor Xa inhibitor were investigated. The patients all received a bolus of andexanet followed by a 2-h infusion of the drug. Twelve hours after the andexanet infusion, clinical hemostasis was adjudicated as excellent or good in 37 of 47 patients in the efficacy analysis. Thrombotic events occurred in 12 of 67 patients (18%), and 15% of the patients died during the 30-day follow-up .